Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation
Anand Gupta, Biostatistician III at Baylor Scott and White Health, shared a post on LinkedIn shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Cardiology, adding:
“Excited to share our latest publication in the American Journal of Cardiology!
Early and Long-Term Outcomes After DOAC Initiation in Hospitalized Patients With Newly Diagnosed Atrial Fibrillation
This study looks at how the timing of direct oral anticoagulant (DOAC) initiation in hospitalized patients newly diagnosed with atrial fibrillation affects both short- and long-term outcomes — an important question given ongoing uncertainty around optimal anticoagulation timing in this population.
Grateful to Subhash Banerjee, my co-authors and collaborators for their contributions to this work.”
Title: Early and Long-Term Outcomes After DOAC Initiation in Hospitalized Patients With Newly Diagnosed Atrial Fibrillation
Authors: Matthew Cervantes, Tariq Jamal Siddiqi, Anand Gupta, Minseob Jeong, Sagar S. Mukhida, Catherine A. Raver, Michael D. Duncan, Byron Cryer, Subhash Banerjee
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events